Clinical and radiological features of idiopathic interstitial pneumonias (IIPs): a pictorial review.
http://www.ncbi.nlm.nih.gov/pubmed/24844883
Read more
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
http://www.ncbi.nlm.nih.gov/pubmed/24836310
Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events.
http://www.ncbi.nlm.nih.gov/pubmed/24639005
Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts.
http://www.ncbi.nlm.nih.gov/pubmed/24613900
Thymosin β4 reduces IL-17-producing cells and IL-17 expression, and protects lungs from damage in bleomycin-treated mice.
http://www.ncbi.nlm.nih.gov/pubmed/24613476
Human lung fibroblasts increase CD4(+)CD25(+)Foxp3(+) T cells in co-cultured CD4(+) lymphocytes.
http://www.ncbi.nlm.nih.gov/pubmed/24076465
Common pathways in idiopathic pulmonary fibrosis and cancer.
http://www.ncbi.nlm.nih.gov/pubmed/23997054
Mapping the future for pulmonary fibrosis: report from the 17th International Colloquium on Lung and Airway Fibrosis.
http://www.ncbi.nlm.nih.gov/pubmed/23682111
Comparative proteome analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP) and organ donors.
http://www.ncbi.nlm.nih.gov/pubmed/23659799
Differentiation of human adipose stem cells into neural phenotype by neuroblastoma- or olfactory ensheathing cells-conditioned medium.
http://www.ncbi.nlm.nih.gov/pubmed/23589068
Interferon-γ and interleukin-17 production from PPD-stimulated PBMCss of patients with pulmonary tuberculosis.
http://www.ncbi.nlm.nih.gov/pubmed/23544607
PI3K p110γ overexpression in idiopathic pulmonary fibrosis lung tissue and fibroblast cells: in vitro effects of its inhibition.
http://www.ncbi.nlm.nih.gov/pubmed/23439433
Thymosin β4 protects C57BL/6 mice from bleomycin-induced damage in the lung.
http://www.ncbi.nlm.nih.gov/pubmed/23320620
Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good.
http://www.ncbi.nlm.nih.gov/pubmed/23047830
Protective effects of thymosin β4 in a mouse model of lung fibrosis.
http://www.ncbi.nlm.nih.gov/pubmed/23045972
A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer.
http://www.ncbi.nlm.nih.gov/pubmed/22903965
Idiopathic pulmonary fibrosis: an altered fibroblast proliferation linked to cancer biology.
http://www.ncbi.nlm.nih.gov/pubmed/22802290
Inhibition of PI3K prevents the proliferation and differentiation of human lung fibroblasts into myofibroblasts: the role of class I P110 isoforms.
http://www.ncbi.nlm.nih.gov/pubmed/21984893
The European IPF Network: towards better care for a dreadful disease.
http://www.ncbi.nlm.nih.gov/pubmed/21454892
